|
|
|
|
pmid:
|
Aubry AF et al. |
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. |
2016 |
AAPS J |
pmid:27350147
|
Björkhem-Bergman L et al. |
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26617265
|
Woolsey SJ et al. |
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26399557
|
Nylén H et al. |
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. |
2014 |
Basic Clin. Pharmacol. Toxicol. |
pmid:24655660
|
Allmyr M et al. |
Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. |
2009 |
Basic Clin. Pharmacol. Toxicol. |
pmid:19686543
|
van de Merbel NC and de Vries R |
Aging of biological matrices and its effect on bioanalytical method performance. |
2013 |
Bioanalysis |
pmid:24066624
|
Xue YJ et al. |
Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. |
2016 |
Bioanalysis |
pmid:26805594
|
Ikegami T et al. |
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. |
2014 |
Biochem. Biophys. Res. Commun. |
pmid:24525121
|
Breuer O et al. |
The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. |
1996 |
Biochim. Biophys. Acta |
pmid:8695664
|
Nury T et al. |
Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. |
2013 |
Biochimie |
pmid:23220593
|
Huang MQ et al. |
Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. |
2014 |
Biomed. Chromatogr. |
pmid:24861746
|
Hukkanen J et al. |
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. |
2015 |
Br J Clin Pharmacol |
pmid:26095142
|
Gjestad C et al. |
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? |
2016 |
Br J Clin Pharmacol |
pmid:26574235
|
de Graan AJ et al. |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. |
2015 |
Br J Clin Pharmacol |
pmid:26119961
|
Kasichayanula S et al. |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. |
2014 |
Br J Clin Pharmacol |
pmid:24837659
|
Gjestad C et al. |
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. |
2017 |
Br J Clin Pharmacol |
pmid:28585378
|
Størset E et al. |
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28146606
|
Mårde Arrhén Y et al. |
A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. |
2013 |
Br J Clin Pharmacol |
pmid:23116409
|
Vanhove T et al. |
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28603840
|